In this era of reform and value-based care, where facilitating successful market access and defining and messaging your value proposition are keys to growth, life sciences companies are challenged to continually innovate and meet changing customer needs.

Our life sciences team has worked with medical device, pharmaceutical and biotech companies to address such business challenges as market access and commercialization, ongoing capital requirements, , entering new markets, working with governmental organizations and evaluation of exit strategies. Baker Tilly’s team provides you with actionable ideas and solutions, including peer-reviewed health economic studies, drawn from our work with hundreds of life sciences companies nationwide. 

  • Transition to ASC 606 with application of new accounting guidance
  • Provide insights regarding implementation of value based care initiatives
  • Fuel growth by harnessing valuable sources of structured and unstructured data
  • Help ensure compliance with applicable HIPAA requirements and government programs
  • Assist in complying with federal and state tax requirements, including state nexus rules
  • Analyze and apply for research and development tax credits
  • Protect your assets from cyber threats
  •  Provide analytics, contracting scenarios and strategies for securing favorable positions with governmental entities
  • Assist with financing needs, including a public offering

We work with privately held and public companies and private equity firms and their portfolio companies through all stages of the life sciences life cycle – from launch to growth to maturity to exit.

If you want a team that understands your industry, gets to know your business intimately and offers profitable solutions while minimizing risk, connect with us.

Life sciences M&A update: H1-2017

Life sciences M&A update: H1-2017

Baker Tilly Capital, LLC’s life sciences M&A newsletter provides an overview of the U.S. medical devices and products, pharmaceutical (pharma) and pharma outsourced services sectors, including recent performance and M&A trends.

Learn more >
ASC 606 implications for life sciences companies

ASC 606 implications for life sciences companies

The revenue recognition standard has specific considerations for life sciences companies.

Learn more >

Our Take

image of Mike D. McKee

“Our team’s experience serving life sciences companies helps you balance innovation, productivity and risk. We can help you stay ahead of industry changes and opportunities throughout your company’s lifecycle.”

— Mike D. McKee Partner, CPA